Address
MaRS Center, South Tower
101 College Street, Suite 300
Toronto, ON, M5G 1L7
Get in touch
(416) 673-8170
We see new ways to deliver drugs
Ripple is a clinical stage ophthalmic therapeutics company focused on sustained drug delivery without the use of polymers or excipients. Our novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors.
Ripple’s Discovery
Epidel™ is founded on a discovery that drugs can be designed to deliver themselves without the need for polymers or excipients. Epidel™ prodrug materials are readily manufactured into implantable forms like cylinders and microspheres. Drug dissolves from the surface of the implant via surface erosion in a highly predictable manner: dose is dictated by implant surface area; duration by implant diameter. The result is an ability to finely tune pharmacokinetics to meet the needs of a target indication with precision control of drug dosing without the bulk added by a polymer.
In the true spirit of invention, Epidel was borne out of constraint. In the mid-1990s, the Controlled Release Field was focused on conjugating drugs into polymer backbones as a way of controlling drug release. While the science was conceptually appealing, the lack of reproducible manufacturing and the complexity of a polydisperse polymeric breakdown profile limited the translation into approval products.
In our Toronto laboratories, these constraints inspired a minimalistic approach to re-think how controlled drug delivery could be achieved. A novel prodrug approach was discovered which provided a simple, highly predictable, and tunable way to achieve sustained drug release without the use of polymers or excipients. Read more.
No polymers. No excipients.
- High drug loading (80%+)
- Smaller implants, no pro-inflammatory degradation products
- Highly tunable drug release and duration via surface erosion
- Simple, scalable, low cost manufacturing processes
Pulled Fiber
Microparticles by emulsion
Extruded Rod
Electro sprayed
Micro particles
Medical Device Coating
Solvent Casting
Powder Coating
Validating the vision timeline
2017
Discovery that prodrugs can be formed into 3 dimensional pharmaceuticals implants without polymers or excipients
2018
Strategic focus on ophthalmology; Retinal implant POC completed; FDA PIND meeting defines 505(b)2
2019
Dexamethasone intravitreal implant PK/PD data confirms safety, efficacy and duration; CMC Tech Transfer to experienced CDMOs
2020
Ripple spun out of IBI; $10M (seed capital + convertible debt) Licensing Agreement signed TOI; $15M Series A Financing; Glaucoma program initiated
2021
First patients treated in Ripple-1 with Dex IVT implant; Key patents granted; Glaucoma implant preclinical POC completed
2022
Ripple-1 Clinical Trial demonstrates biological effect, duration and safety of Dex IVT implant; Glaucoma implant PK/PD data confirms safety & efficacy
Partners
In October of 2022, we signed an exclusive Licensing Agreement for our lead retina product (IBE-814 IVT) for China with CS Pharmaceuticals ("CSP"), a British headquartered multinational company focused on the development and commercialization of rare disease and ophthalmology products in China.
See
Press Release.
We are also working with a number of Pharma partners interested in evaluating our extended-release prodrug technology with their proprietary APIs.
We are also pleased to work with the following product development partners:
About us
Our leadership team has experience in managing both small and large public and private companies through various stages of growth and financing strategies (venture capital, M&A transactions, IPOs, PIPEs). They successfully sold the surface modification business of Interface Biologics to Evonik (ETR:EVK) in 2019 and founded Ripple Therapeutics in January of 2020.
Our team is made up of a high calibre group of PhD and MSc Chemists, Engineers and Material Scientists.
News & Updates
